Analyzing Zevra Therapeutics (NASDAQ:ZVRA) and Sigyn Therapeutics (OTCMKTS:SIGY)

Sigyn Therapeutics (OTCMKTS:SIGY) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Insider & Institutional Ownership

10.0% of Sigyn Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 78.5% of Sigyn Therapeutics shares are held by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Sigyn Therapeutics and Zevra Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sigyn Therapeutics	0	0	0	0	0.00
Zevra Therapeutics	1	1	6	0	2.63

Zevra Therapeutics has a consensus price target of $22.80, suggesting a potential upside of 164.19%. Given Zevra Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Zevra Therapeutics is more favorable than Sigyn Therapeutics.

Profitability

This table compares Sigyn Therapeutics and Zevra Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sigyn Therapeutics	N/A	N/A	-3,743.20%
Zevra Therapeutics	41.93%	-51.40%	-19.40%

Earnings & Valuation

This table compares Sigyn Therapeutics and Zevra Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sigyn Therapeutics	N/A	N/A	-$3.34 million	($4.19)	-0.16
Zevra Therapeutics	$23.61 million	20.58	-$105.51 million	$0.47	18.36

Sigyn Therapeutics has higher earnings, but lower revenue than Zevra Therapeutics. Sigyn Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Sigyn Therapeutics has a beta of -0.72, suggesting that its share price is 172% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.

Summary

Zevra Therapeutics beats Sigyn Therapeutics on 10 of the 13 factors compared between the two stocks.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.

About Zevra Therapeutics

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.